Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 38 - Medicinal preparations containing peptides
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
10/2002
10/03/2002WO2002077235A2 Intracellular signaling molecules
10/03/2002WO2002077234A2 Compositions and methods relating to colon specific genes and proteins
10/03/2002WO2002077232A2 Compositions and methods relating to breast specific genes and proteins
10/03/2002WO2002077226A1 Prostaglandin ep1 receptor
10/03/2002WO2002077218A1 Coagulation factor vii derivatives
10/03/2002WO2002077217A2 Human dual specificity protein phosphatase 7-like protein
10/03/2002WO2002077216A2 Ikk2 variant, dino gene, lectin-like receptor gene, and proteins encoded thereby
10/03/2002WO2002077199A2 Methods and products related to fgf dimerization
10/03/2002WO2002077198A2 Methods of modulating angiogenesis
10/03/2002WO2002077193A2 Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof
10/03/2002WO2002077191A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
10/03/2002WO2002077189A2 Glycosylation-resistant and nonglycosylated cyanovirins
10/03/2002WO2002077188A2 Human serine/threonine kinase
10/03/2002WO2002077187A2 Proteins producing an altered immunogenic response and methods of making and using the same
10/03/2002WO2002077186A2 Human secreted proteins
10/03/2002WO2002077180A2 Novel nucleic acids and polypeptides
10/03/2002WO2002077174A2 Human cytokine receptor
10/03/2002WO2002077167A2 Isolated human protease proteins, nucleic acid molecules encoding human protease proteins, and uses thereof
10/03/2002WO2002077164A2 Isolated human aminoacylase, nucleic acid molecules encoding human aminoacylase, and uses thereof
10/03/2002WO2002077161A2 Production of high levels of trangenic factor ix without gene rescue, and its therapeutic uses
10/03/2002WO2002077156A2 Protection-of-telomere-1 (pot-1) protein and encoding polynucleotides
10/03/2002WO2002077155A2 Keratinocyte growth factor-2
10/03/2002WO2002077034A2 Modified granulocyte colony stimulating factor (g-csf) with reduced immunogenicity
10/03/2002WO2002077033A1 Antibodies against cancer
10/03/2002WO2002077031A1 Thrombin derivatives and process for producing the same, anhydrothrombin derivatives and process for producing the same, platelet agglutination-inducing compositions, method of inducing platelet agglutination, clinical test reagents, clinical test method, thrombosis inhibitors, adsorbent and process for producing the same,
10/03/2002WO2002077030A2 Modified mhc molecules whose binding to cd8 or cd4 is inhibited and use thereof
10/03/2002WO2002077029A2 Cd19-specific redirected immune cells
10/03/2002WO2002077028A1 Polypeptides and nucleic acids for bolekine
10/03/2002WO2002077027A1 Human stra6-like protein and nucleic acids encoding the same
10/03/2002WO2002077025A1 Peptide analogues of myelin basic protein epitopes in the treatment of experimental autoimmune encephalomyelitis (eae) and multiple sclerosis (ms)
10/03/2002WO2002077024A1 Shellfish protein
10/03/2002WO2002077023A2 A new essential downstream component of the wingless signalling pathway
10/03/2002WO2002077021A2 Streptococcus pneumoniae proteins and nucleic acids
10/03/2002WO2002077019A1 Methods and compositions for modulating tumor suppression
10/03/2002WO2002077017A2 Medical uses of intercellular communication facilitating compounds
10/03/2002WO2002077015A1 Isolated human g-protein coupled receptors, nucleic acid molecules encoding human gpcr proteins, and uses thereof
10/03/2002WO2002077013A2 Human secreted proteins
10/03/2002WO2002077010A2 Method of preventing t-cell mediated responses by map proteins
10/03/2002WO2002077006A1 Bone morphogenic protein polynucleotides, polypeptides, and antibodies
10/03/2002WO2002077001A2 Novel receptors
10/03/2002WO2002076508A1 Methods for delivering nucleic acid molecules into cells and assessment thereof
10/03/2002WO2002076507A2 Uses of opg ligand to modulate immune responses
10/03/2002WO2002076505A1 Remedies for post-traumatic stress disorder
10/03/2002WO2002076504A1 Remedies for inflammatory bowel diseases
10/03/2002WO2002076503A1 Treatment of central nervous system diseases by antibodies against glatiramer acetate
10/03/2002WO2002076501A2 Blood cell production via activation of the hemoglobin scavenger receptor
10/03/2002WO2002076497A2 Method and composition
10/03/2002WO2002076496A1 Anthrax lethal factor inhibits tumor growth and angiogenesis
10/03/2002WO2002076495A1 Insulin preparations, which do not contain any zinc or only a small quantity of zinc and which have an improved stability
10/03/2002WO2002076494A2 USE OF CYTOKINES OF THE TGF-β SUPERFAMILY FOR THE TREATMENT AND DIAGNOSIS OF SKIN RELATED DISORDERS
10/03/2002WO2002076493A1 Novel drugs for preventing/treating immunopathic diseases
10/03/2002WO2002076492A1 Novel agents for ameliorating motor disorder
10/03/2002WO2002076491A1 Liposome targeting of matrix metalloproteinase inhibitors
10/03/2002WO2002076490A1 Compounds comprising disulfide-containing peptides and nitrogenous bases, and medical uses thereof
10/03/2002WO2002076489A1 Serum albumin binding moieties
10/03/2002WO2002076488A1 Human secreted proteins
10/03/2002WO2002076487A1 Anticancer agents containing antigenotoxic and immunostimulative peptides produced from the hydrolysate of silkworm cocoon
10/03/2002WO2002076486A2 Histidine-rich glycoprotein
10/03/2002WO2002076484A2 Combination of a taxane and a cyclin-dependent kinase inhibitor
10/03/2002WO2002076483A2 Bacteriophage preparation
10/03/2002WO2002076482A2 USE OF IKK-β INHIBITORS AND METHOD FOR DISCOVERY OF SAID INHIBITORS
10/03/2002WO2002076468A1 Tumor therapy with alphavirus-based and high affinity laminin receptor-targeted vectors
10/03/2002WO2002076467A1 Compositions and methods to regulate bone and mineral metabolism
10/03/2002WO2002076452A1 Use of melationin in the manufacture of a medicament for treating attention deficit hyperactive disorder
10/03/2002WO2002076448A1 Molecular conjugates for use in treatment of cancer
10/03/2002WO2002076437A2 Methods for treating neurodegenerative diseases including alzheimer's
10/03/2002WO2002076394A2 Enzyme-based anti-cancer compositions and methods
10/03/2002WO2002076391A2 Microbial feeds for aquaculture and agriculture
10/03/2002WO2002076389A2 Compositions and methods to prevent metastasis from primary malignancies
10/03/2002WO2002076388A2 Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting gm1-ganglioside
10/03/2002WO2002076386A2 Method of inducing proliferation of retinal stem cells
10/03/2002WO2002076380A2 Cytotoxic factors for modulating cell death
10/03/2002WO2002076240A1 Health foods containing natto kinase and fermented milk porducts
10/03/2002WO2002076208A1 Regulation of weight
10/03/2002WO2002076173A2 Inhibitors of glycosaminoglycans
10/03/2002WO2002068687A8 Function and application of tob gene in central nervous system of mammal
10/03/2002WO2002066497A3 Tetrapeptide regulating prostate functions and its compositions and methods
10/03/2002WO2002062944A3 Novel physiologically active peptide and use thereof
10/03/2002WO2002062818A3 Antisense modulation of casein kinase 2-alpha expression
10/03/2002WO2002062297A3 Methods and compositions for modulating gluconeogenesis using pgc-1
10/03/2002WO2002059153A3 Anticoagulants and their uses
10/03/2002WO2002058728A3 Polypeptides capable of binding to cd64 and comprising one or more heterologous t cell epitopes, and their uses
10/03/2002WO2002055533A3 Methods of using imxp-888 and imxp-888 antagonists
10/03/2002WO2002055109A3 Generation and/or reduction of new lung tissue in an affected lung, by modulation of the wnt-pathway
10/03/2002WO2002051436A3 Stable enzymatic wound debrider
10/03/2002WO2002046226A3 Trefoil factor 2 (tff2) peptides with moiety attached to asn15
10/03/2002WO2002034933A3 Methods and compositions for modifying biologically active target molecules
10/03/2002WO2002029086A3 Nucleic acid sequences differentially expressed in cancer tissue
10/03/2002WO2002026193A3 Use of cyr61 in the treatment and diagnosis of human uterine leiomyomas
10/03/2002WO2002024866A3 Method of inducing apoptosis in lymphoid cells
10/03/2002WO2002022677A3 Variants of allergenic proteins of the group 2 of dermatophagoides
10/03/2002WO2002022657A3 Peptide antagonist of multiple chemokine receptors and uses thereof
10/03/2002WO2002018407A3 Antisense oligonucleotides against vanilloid receptor 1
10/03/2002WO2002014349A3 Non-covalent inhibitors of urokinase and blood vessel formation
10/03/2002WO2002012188A3 Indole compounds useful for the treatment of cancer
10/03/2002WO2002010195A3 Modified peptides with increased potency
10/03/2002WO2002009735A3 Methods and devices to modulate the wound response
10/03/2002WO2002002751A3 Alteration of cell membrane
10/03/2002WO2002000242A3 Human papilloma virus treatment
10/03/2002WO2001098515A3 Gene-regulating conjugates
1 ... 1982 1983 1984 1985 1986 1987 1988 1989 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002 ... 3163